We are a clinical-stage nanomedicine platform company developing Accurins™, a new class of targeted and programmable therapeutics developed using our Medicinal Nanoengineering® platform. Accurins are nanoparticles designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease, enhancing efficacy while minimizing adverse effects on healthy tissues. We are developing our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies.
Our lead drug candidate, BIND-014, is currently enrolling patients with KRAS mutant or squamous histology non-small cell lung cancer (NSCLC) in a Phase 2 clinical trial called iNSITE1. We are also evaluating BIND-014 in patients with urothelial carcinoma, cholangiocarcinoma, cervical cancer and squamous cell carcinoma of the head and neck in a second Phase 2 trial called iNSITE2. Our second proprietary drug candidate, BIND-510, is a prostate-specific membrane antigen (PSMA)-targeted Accurin nanoparticle containing vincristine and is currently in preclinical development. The company has collaborated or is collaborating with Pfizer, AstraZeneca, Roche, Merck, Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals, Inc.) and Amgen to develop Accurins based on therapeutic payloads and targeting ligands from their product pipelines.